KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash & Current Investments (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Cash & Current Investments data on record, last reported at $238.4 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 50.8% year-over-year to $238.4 million; the TTM value through Dec 2025 reached $238.4 million, down 50.8%, while the annual FY2025 figure was $238.4 million, 50.8% down from the prior year.
  • Cash & Current Investments reached $238.4 million in Q4 2025 per PCRX's latest filing, down from $246.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $693.9 million in Q3 2021 and bottomed at $174.0 million in Q1 2023.
  • Average Cash & Current Investments over 5 years is $398.7 million, with a median of $366.5 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 97.86% in 2021, then tumbled 61.52% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $656.4 million in 2021, then plummeted by 56.03% to $288.7 million in 2022, then dropped by 3.49% to $278.6 million in 2023, then surged by 73.96% to $484.6 million in 2024, then tumbled by 50.8% to $238.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $238.4 million in Q4 2025, $246.3 million in Q3 2025, and $445.9 million in Q2 2025.